GW & Wade’s Jazz Pharmaceuticals JAZZ Stock Holding History

GW & Wade’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,597	Closed	-$964K	–	246
2018 Q2	$964K	Hold	5,597	–	–	0.11%	113
2018 Q1	$845K	Hold	5,597	–	–	0.1%	115
2017 Q4	$754K	Buy	+5,597	New	+$776K	0.09%	114

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

GW & Wade's JAZZ Position: Q3 2018 in Review

GW & Wade sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2018, closing a stake of 5,597 shares — an estimated $964K sold.

GW & Wade first reported a position in JAZZ in Q4 2017 and held it in 3 quarters. The position peaked at $964K in Q2 2018. 403 funds tracked by Wall St. Rank hold JAZZ as of Q3 2018.

GW & Wade reported no remaining Jazz Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
GW & Wade sold 5,597 Jazz Pharmaceuticals shares in Q3 2018, an estimated $964K.
GW & Wade first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 3 quarters.
GW & Wade's Jazz Pharmaceuticals position peaked at $964K in Q2 2018.
403 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2018.

Based on GW & Wade's 13F filing for Q3 2018, filed 7 Nov 2018.